NCT05473910 - A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

AMLMyelodysplastic SyndromesALL, Adult

Interventions

DRUG

SOC + TSC-100

HA-1 positive

DRUG

SOC + TSC-101

HA-2 positive or HA-1 negative

OTHER

Control

SOC alone

Trial Locations (15)

10027

RECRUITING

Columbia University, New York

19104

RECRUITING

UPenn, Philadelphia

21287

RECRUITING

John Hopkins University, Baltimore

27599

RECRUITING

University North Carolina, Chapel Hill

30342

RECRUITING

Northside Hospital, Atlanta

33021

RECRUITING

Memorial Healthcare System, Hollywood

48201

RECRUITING

Karmanos Cancer Institute, Detroit

53226

RECRUITING

Froedert and Medical College of Wisconsin, Milwaukee

75246

RECRUITING

Baylor University Medical Center, Dallas

77030

RECRUITING

MD Anderson, Houston

91010

RECRUITING

City of Hope, Duarte

06510

RECRUITING

Yale, New Haven

02114

RECRUITING

Mass General Hospital, Boston

07601

RECRUITING

Hackensack University Medical Center, Hackensack

10029-6696

RECRUITING

Mount Sinai, New York

All Listed Sponsors

lead

TScan Therapeutics, Inc.

INDUSTRY